Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001174607 | SCV001337801 | likely benign | not specified | 2020-01-22 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV001179935 | SCV001344738 | likely benign | Hereditary cancer-predisposing syndrome | 2022-12-06 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002068121 | SCV002327520 | likely benign | Familial melanoma | 2023-08-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001179935 | SCV002678535 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-01-08 | criteria provided, single submitter | clinical testing | The c.84G>A variant (also known as p.V28V) is located in coding exon 1 of the CDKN2A gene. This variant results from a G to A substitution at nucleotide position 84. This nucleotide substitution does not change the valine at codon 28. This nucleotide position is well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration may result in the creation or strengthening of a novel splice donor site; however, direct evidence is insufficient at this time (Ambry internal data). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |